A Phase 1/2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies (NCT07249905)

This trial is Coming soon

Registration number NCT07249905

This study is designed to characterise the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma.

Program & service

This trial is being run with the Cancer service, and as part of the Haematology program.

Trial phase

Phase 1

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Dr Maciej Tatarczuch

Key inclusion data

Adults ≥ 18 years with relapsed, progressive, or refractory B-cell malignancies (e.g. DLBCL, FL, MCL, marginal zone lymphoma, transformed indolent lymphoma, WM). At least 2 prior lines of therapy (including an anti-CD20 mAb-containing chemotherapy combination regimen); MCL participants must have failed or be intolerant to a BTKi. Measurable disease on CT/MRI/PET-CT (nodal lesion >1.5cm or extranodal lesion >1.0cm). Primary CNS lymphoma or known CNS involvement by lymphoma is exclusionary.

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.